Harvard Apparatus Regenerative Technology 3Q 2026: Revenue $145K, EPS ($0.08) — 10-Q Summary
Harvard Apparatus Regenerative Technology reported 3Q 2026 revenue of $145K, up 18% YoY, and a net loss of $1.46M, down 14%. Growth came from higher shipments to Health Regen, while R&D costs fell 67% due to lower clinical trial expenses. The company expects current cash to fund operations into 1Q 2027 but needs additional capital.
How this was made

The 30-second read
Why it matters
The earnings beat on loss reduction may attract short‑term buying interest, but the small scale limits broader market impact.
Market read
Primary earnings disclosure for a micro‑cap; limited but immediate relevance for traders holding or shorting HRGN.
What to watch
Potential need for additional capital and reliance on a single clinical site could limit upside.
Background
Harvard Apparatus Regenerative Technology filed its Q3 2026 10‑Q, reporting modest revenue growth and a narrowed net loss.
Ticker impact
Q3 2026 10‑Q shows revenue $145K (+18%) and net loss narrowing to $1.46M, EPS improving to -$0.08.
likely modest upside as the market prices in the loss improvement.
The company is still loss‑making, but the 14% loss reduction and revenue increase are positive signals for a micro‑cap.
Market effects
Limited; reflects modest growth in the regenerative‑medicine niche.
Minimal; company is small and US‑focused.
Low
Counterpoint
Despite narrowing losses, the company remains cash‑negative and may need dilutive financing, which could pressure the stock.
Key entities
- companyHarvard Apparatus Regenerative Technology, Inc.
Micro‑cap biotech reporting Q3 2026 results.





